NCT06224920Completed
Activity of Cerebral Networks, Amyloid and Microglia in Aging and Alzheimer's Disease
Aktivität Von Zerebralen Netzwerken, Amyloid Und Mikroglia Bei Alterung Und Alzheimer-Krankheit
Source: ClinicalTrials.gov · Last updated 4 Jul 2025
Brief summary (registry, in English)
The temporal sequence of microglial activation, changes in functional and structural connectivity and the progression of neurocognitive deficits has not been conclusively clarified. To date, there have been no studies of the topographical and pathogenetic relationship between microglial activation and network degeneration. The main aim of the present study is to investigate the relationships between functional, structural MRI connectivity and microglial activation at different stages of AD in a multimodal approach. Genetic predisposition and biomarkers in blood and cerebrospinal fluid will also be taken into account in order to close the explanatory gap in pathogenesis between the known molecular pathological changes and their effects at system level in an integrative approach.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 140 (actual)
- First submitted
- 16 Jan 2024
- Start date
- 1 Jan 2017
- Primary completion date
- 1 Jan 2024
- Lead sponsor
- Ludwig-Maximilians - University of Munich
- Diseases
- Alzheimer disease
- NCT number
- NCT06224920
What you commit to
- Study type: Observational
- Participants enrolled: 140
- From 1 Jan 2017 to the primary completion date, 1 Jan 2024
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Other severe concomitant psychiatric illnesses, e.g. schizophrenia, bipolar affective disorder
- Drug, medication or alcohol abuse at the time of the study
- Any electronic implants (e.g. pacemakers) or other MRI and/or PET contraindications
- Occupational or other radiation exposure \>15 mSv/a
Other illness
- Severe neurological diseases (such as disc prolapse in the last 6 months, sensory, motor or autonomic polyneuropathies)
- Severe internal diseases (such as manifest arterial hypertension, severe heart disease, pacemaker, respiratory insufficiency)
- Malignant diseases of any kind in the last 5 years, severe active infectious diseases, chronic and systemic skin diseases
- Bone diseases (such as Paget's disease, osteoporosis with spontaneous fractures, recent fractures)
Other
- Existence of legal guardianship/restricted capacity to consent
- Clinically relevant depressive symptoms (Beck Depression Inventory, BDI, score \> 17/GDS \> 5)
- Acute suicidal tendencies
- Severe traumatic brain injury (\> 2nd degree TBI) in the medical history or 1st degree within the last 3 months.
- Evidence of structural damage to the basal ganglia or brainstem
- Other circumstances which, in the opinion of the investigator, speak against the patient's participation in this study
Who the study is looking for
- Informed consent for the additional examinations, written declaration of consent
- Constant pharmacotherapy in a period of one week before the MRI/EEG/PET examination
Age in the registry: 55 years to 80 years · Sex: All
Related publications
- Microglial dynamics associate with the spatial pattern of tau deposition in early Alzheimer's disease.Alzheimers Res Ther · 2026 · PMID 42875788
This page is information, not medical advice. Discuss any trial with your doctor.